The anticancer role of aurora kinase inhibitors

XIA Liang-ping,ZHOU Fei-fei,LIU Qiang

DOI: https://doi.org/10.3969/j.issn.1009-0460.2009.10.020

2009-01-01

Chinese Clinical Oncology

Abstract:Aurora kinase inhibitors are new member of the family of targeted agents.Not only aurora kinases have strong correlation with tumor but also the anticancer efficacy of aurora kinase inhibitors,as monotherapy,were demonstrated in variety of cancer types,even,some of the inhibitors are ongoing phase Ⅰ clinical trails.The emerging research in cancer cell lines showed that the combination of aurora kinase inhibitors and traditional chemotherapy agents such as taxanes,TMZ,vincristine,CDDP,and VP-16 was more effective than the each treatment alone.Aurora kinase inhibitors can override the chemoresistance caused by E2;aurora kinase inhibitors can enhance the sensitivity of radiotherapy to cancer.However,the role of aurora kinase inhibitors depends strongly on the p53 status: only the cancer cells with mutated p53 or no-functional p53 can benefit from the combination with radiotherapy or TMZ.